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Abstract. The serodiagnostic potential of recombinant ORFF protein (rORFF) from Leishmania infantum was
assessed by ELISA. Of 49 sera from confirmed cases of visceral leishmaniasis (VL), all were seropositive using 5
ng of rORFF and serum diluted 1:20, while only 38 were positive with 500 ng of soluble antigen (SA) and 44 were
positive by a direct agglutination test. There was also a positive correlation between spleen size and level of sero-
positivity with rORFF or SA. The reciprocal endpoint titer with rORFF was 1,280 for sera from VL patients, but ,
20 with sera from malaria, filariasis, and tuberculosis patients, as well as with sera from healthy individuals from
endemic and non-endemic areas. Sera from 10 confirmed cutaneous leishmaniasis cases from Turkey were negative
or only weakly positive with rORFF, although 9 were positive with SA. Thus, rORFF protein appears useful as a
sensitive reagent for the differential diagnosis of VL caused by the Leishmania donovani complex.
Protozoan parasites of the genus Leishmania cause a spec-
trum of human disease ranging from self-limiting cutaneous
leishmaniasis (CL) to the lethal visceral leishmaniasis (VL).
There is a general correlation between the species of Leish-
mania and the type of disease, with the Leishmania donovani
complex causing VL or kala-azar. Routine diagnosis of VL
has long been based on the microscopic detection of para-
sites in smears of lymph node, bone marrow, or splenic as-
pirates or culturing the parasite from patient material. These
surgical procedures for diagnosis are painful and dangerous1;
thus, there is an urgent need for safe and reliable tests for
specific diagnosis of leishmaniasis.
Serologic tests that have been developed and evaluated
clinically include an immunofluorescent antibody test
(IFAT),2–4 an ELISA with either whole parasites or purified
antigens,5–10 a dot-ELISA,11,12 immunoblot analysis,13,14 and
the direct agglutination test (DAT).15–18 The DAT using mi-
crotiter plates for the diagnosis of VL and American CL
gives satisfactory results and is easy to perform.19 It is a
simple technique with high sensitivity and specificity.15,18
One of its major drawbacks is that it has no prognostic value
for evaluating the progression of the disease. The DAT is
used as a routine serologic test for VL in India, and the
parameters of the test have been established under local con-
ditions with very little false positivity.18,20
In this paper, we report the serodiagnostic potential for
Indian VL of recombinant ORFF protein (rORFF) that is
encoded in the LD1 locus of chromosome 35 of L.
infantum.21 The rORFF appears to be specifically recognized
by sera from patients with VL compared with those with
CL. Furthermore, the sensitivity of detection appears to be
greater than with total L. donovani promastigote soluble an-
tigen, suggesting the utility of rORFF protein as a sensitive
and differential diagnostic reagent.
MATERIALS AND METHODS
Patient sera. Sera were collected from 49 patients with
clinically confirmed VL in the Sahibganj and Godda districts
of Bihar, India, where kala-azar is endemic. Sera were also
collected from 22 suspected VL cases, four patients who
were intermittently treated for VL, and three uninfected in-
dividuals from the same region. Diagnosis of VL patients
was based on the clinical symptoms such as persistent fever,
splenomegaly, anemia, and weight loss. The patients were
predominantly males and less than 10 years of age. Clini-
cally diagnosed cases were also assessed by the DAT, which
shows a very high degree of specificity and sensitivity for
VL.18 The DAT endpoint titers from Indian VL patient sera
had titers . 1:500, which are generally considered positive
for all leishmanial infections.16 Sera were collected from 10
patients in Turkey with CL, presumably due to infection with
L. major or L. tropica, and from 7 healthy individuals from
non-endemic areas of India with no history of exposure to
Leishmania. Sera were also collected from 18 Indian patients
who were diagnosed with malaria, tuberculosis, or filarial
infection by standard serologic and microscopic methods.
Informed consent was obtained from patients or their rela-
tives before sample collection, in accordance with the guide-
lines indicated by the Jawaharlal Nehru University Ethical
Review Committee.
Preparation of Leishmania antigens. Soluble antigen
was prepared from promastigotes of L. donovani AG83
(MHOM/IN/83/AG83). The cells were harvested, washed
three times with phosphate-buffered saline (PBS), pH 7.2, at
48C, followed by sonication. The lysate was centrifuged at
12,000 3 g (Sorvall RC5c centrifuge, SS34 rotor; Dupont,
Newtown, CT) for 15 min at 48C. The supernatant was col-
lected and the protein concentration was estimated by the
Lowry method.22 This protein was used as soluble antigen
(SA). Recombinant ORFF antigen from L. infantum (rORFF)
was prepared essentially as described previously.23 The 858-
basepair ORFF gene21 was amplified by the polymerase
chain reaction from clone pB30 and cloned into Xho I plus
Bam HI-digested pET17b (Novagen, Inc., Madison, WI).
The recombinant protein was expressed in Escherichia coli
BL21 cells (Novagen) after induction with isopropyl-p-D-
thiogalactopyranoside. The bacterial pellet was dissolved se-
quentially in 2 M, 4 M, 6 M, and 8 M urea. The rORFF (34
kD) dissolved only in the 8 M fraction, where it constituted
the vast majority of protein visible by staining with Coom-
assie brilliant blue after separation by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis. The 8 M fraction
was dialyzed several times against PBS to remove urea and
protein was concentrated by precipitation with (NH4)2SO4.
The precipitated rORFF was dissolved in PBS and protein
concentration was determined as above.
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FIGURE 1. Titration curves comparing recombinant ORFF (r-
ORFF) antigen and total promastigote soluble antigen (SA). Various
amounts of antigen prepared as described in the Materials and Meth-
ods were tested by ELISA using a 1:10 dilution of serum from the
same patient with visceral leishmaniasis. Values represent mean of
the two values with standard deviations , 5% of the mean. OD405
5 optical density at 405 nm.
TABLE 1
Sensitivity and specificity of DAT, rORFF- and SA-based ELISA for
detection of visceral leishmaniasis (VL)*
Infection status Number Spleen size
Percentage positive
DAT rORFF SA
Confirmed VL
Suspected VL
Intermittently treated
Endemic normals
Non-endemic normals
49
22
4
3
5
5–12 cm
3–4 cm
2 cm
Unknown
Unknown
90
91
50
0
0
100
95
100
33
0
78
86
50
33
0
* DAT 5 direct agglutination test; rORFF 5 recombinant ORFF; SA 5 soluble antigen.
Serodiagnostic assays. The DAT was carried out essen-
tially as described.15 Antigen for the test was prepared from
trypsin-treated, Coomassie brilliant blue–stained, formalin-
preserved promastigotes of L. donovani AG83. Agglutina-
tion was carried out using a 1:500 dilution of patient sera in
PBS containing 1% fetal bovine serum. The test was read
visually after overnight incubation at 228C. The ELISAs
were carried out in polystyrene microtiter plates essentially
as described earlier.8 The optimal concentrations of rORFF
and SA to be used for coating the plates and optimal dilution
of the patient sera were standardized by performing initial
ELISAs with various concentrations of the antigen and di-
lutions of sera. Subsequently, ELISA plates were coated with
5 ng of rORFF or 500 ng of SA (optimal concentrations) in
50 ml of PBS, pH 7.5. The wells were blocked with 200 ml
of 3% bovine serum albumin (BSA) in PBS for 1–2 hr at
378C. After the wells had been washed three times with PBS,
0.1% Tween 20, they were incubated with 50 ml of serum
diluted in PBS plus 1% BSA for 2 hr at 378C. Serum dilu-
tions were usually 1:20 for rORFF and 1:100 for SA, except
for endpoint titrations where two-fold dilutions of sera start-
ing at 1:20 were used. The wells were then washed three
times with PBS, 0.1% Tween 20, incubated with 50 ml of
goat anti-human-IgG conjugated with alkaline phosphatase
(Sigma, St. Louis, MO) diluted 1:2,000 in PBS plus 1% BSA
for 1–2 hr at 378C, and rinsed three times with PBS, 0.1%
Tween 20. After incubation for 30 min at room temperature
with 50 ml of p-nitrophenylphosphate (Sigma), the reaction
was stopped with 50 ml of 3N NaOH. The optical density at
405 nm (OD405) of each well was determined using ELISA
plate reader (7520 ELISA Reader; Cambridge Technology,
Inc., Watertown, MA). Each serum sample was assayed in
duplicate. Serum samples giving OD405 values greater than
the mean OD405 plus three standard deviations for nonin-
fected, non-endemic controls (0.429 or 0.633 for ORFF, de-
pending on the set of sera from healthy individuals, and
0.445 or 0.735 for SA) were considered seropositive.
RESULTS
Recombinant ORFF antigen from L. infantum (rORFF) is
a sensitive VL serodiagnostic using ELISA. A 1:10 dilution
of serum from a parasitologically confirmed VL patient re-
acted strongly with rORFF at concentrations as low as 10
ng/well (Figure 1). In contrast, there was little signal over
background with less than 100 ng of total SA from L. don-
ovani promastigotes. Thus, the serodiagnostic assay using
rORFF is at least 10 times more sensitive than that using
SA. A series of ELISAs using different concentrations of
rORFF or SA with various dilutions of patient sera led to
optimization of the assays using 5 ng of rORFF with a 1:20
dilution of sera or 500 ng of SA with a 1:100 dilution of
sera. These conditions were used for subsequent analyses.
Serum samples from 49 clinically confirmed VL patients
in Bihar, India were compared using the DAT and the SA-
and rORFF-based ELISAs (Table 1). Forty-four of 49 sera
(90%) tested positive by the DAT, based on an agglutination
titer . 1:500. Only thirty-eight of the 49 sera (77%) tested
positive by the ELISA using 500 ng of SA per well and a
1:100 dilution of the sera. When 500 ng of SA was used
with a 1:20 dilution of sera, significant false-positive results
were obtained with sera from malaria patients and from
healthy individuals from endemic or nonendemic areas. In
contrast, all (100%) of the 49 sera were positive by the
ELISA using 5 ng of rORFF per well and a 1:20 dilution of
sera. Sera from noninfected individuals from nonendemic
areas (negative controls) gave the lowest ELISA readings
(mean 6 SD OD405 5 0.256 6 0.058). Sera from the three
uninfected individuals from the endemic area showed a
mean OD405 value of 0.438 6 0.051, which is slightly above
the cut-off value. This may reflect an undocumented history
of Leishmania infection in these patients. All five of the
confirmed VL sera that were negative by the DAT were pos-
itive by the rORFF-based ELISA. In these cases, the OD405
values were low (between 0.438 and 0.679), suggesting a
low level of antibody and perhaps, by extension, a low par-
asitemia, although their spleen sizes (5–6 cm), were indic-
ative of significant infection.
Sera from 22 patients with suspected VL and 4 that were
intermittently treated for VL were also tested by the DAT
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FIGURE 2. Spleen size and antibody levels in patients with visceral leishmaniasis (VL). Sera from 49 clinically confirmed patients with VL
(spleen sizes $ 5cm), 22 clinically suspected cases (spleen sizes 5 3–4 cm), 3 uninfected endemic normal (healthy) individuals, and 5
uninfected non-endemic controls were assayed by ELISA. A, 5 ng of recombinant ORFF (rORFF) antigen using a 1:20 dilution of sera. B,
500 ng of soluble antigen (SA) using a 1:100 dilution of sera. The horizontal line indicates the cut-off value (mean optical density at 405 nm
[OD405] 1 3 SD for five healthy controls from non-endemic areas) used to determine a positive result. The horizontal bars indicate the mean
OD405 values for each range of spleen sizes or control group. Those means that are significantly different from the uninfected endemic controls
(using the Student’s t-test) are indicated by ** (P , 0.001), * (P , 0.01), 1 (P , 0.02), or # (P , 0.05).
and the SA- and rORFF-based ELISAs (Table 1). Twenty
(91%) of the former and two (50%) of the latter tested pos-
itive by the DAT, while 19 (86%) and two (50%), respec-
tively, tested positive using the SA-based ELISA. In con-
trast, all but one (95%) of the suspected VL cases and all of
the intermittently treated patients were positive by the r-
ORFF-based ELISA. Indeed, the mean OD405 value for the
latter group (1.282 6 0.437) was as high as that for the
confirmed VL cases (1.201 6 0.461).
Examination of the VL patients showed a correlation be-
tween spleen size and serum antibody levels as determined
by the rORFF- and SA-based ELISAS. The OD450 values in
the rORFF ELISA ranged between 0.540 and 2.181 for sera
from different VL patients, with spleen sizes ranging from
3 to 12 cm. Mean OD405 values for each spleen size were
significantly higher than both non-endemic and endemic
controls in all cases, except for patients with 6-cm spleens
tested using the SA-based ELISA (Figure 2). There was a
clear linear relationship between OD405 and spleen size (r2 5
0.34, P , 0.001; Figure 2A). A similar correlation was ob-
tained using the SA-based ELISA when 500 ng of SA and
a 1:100 dilution of sera was used, although the linear rela-
tionship was less pronounced (r2 5 0.17, P , 0.001; Figure
2B). Analysis using the nonparametric Spearman rank order
correlation test generated similar statistics (r 5 0.650, P ,
0.001 for the rORFF ELISA and r 5 0.403, P , 0.001 for
the SA-based ELISA).
The rORFF-based ELISA showed specificity for VL com-
pared with other endemic diseases. The endpoint titers of
sera from 15 VL patients ranged from 1:80 to 1:1,280 for
VL sera, but were less than 1:20 with sera from uninfected
individuals from endemic and non-endemic areas, as well as
from patients infected with malaria, filaria, and tuberculosis
(Figure 3). The rORFF-based ELISA was also able to dis-
criminate between patients with VL and CL. Of the 10 sera
(diluted 1:20) from parasitologically confirmed CL patients
(presumably infected with L. major or L. tropica), four
showed only a marginal reaction with rORFF (mean OD405
5 0.763 6 0.024 versus a cut-off value of 0.633 for sera
from healthy individuals) (Figure 4). The remaining sera had
OD405 values below the cut-off value and thus showed no
significant reaction with rORFF. In contrast, 9 of the 10 sera
(diluted 1:100) showed a positive reaction with L. donovani
SA, although two were only slightly higher than the cut-off
value (0.735). The mean OD405 value (2.156 6 0.759) for
these sera was significantly greater (P , 0.001) than that for
the control sera using the SA-based ELISA, but not for the
rORFF-based ELISA.
DISCUSSION
This study shows that rORFF has substantial potential as
an antigen for the serodiagnosis of L. donovani infection.
An ELISA proved to be sensitive with as little as 5 ng of
485SERODIAGNOSIS OF LEISHMANIASIS
FIGURE 3. Specificity of the recombinant ORFF (rORFF) ELISA for Leishmania infection. Reciprocal endpoint titers of sera from patients
with visceral leishmaniasis (n 5 15), malaria (n 5 6), filariasis (n 5 6), tuberculosis (n 5 6), or uninfected individuals from non-endemic (n5
8) or endemic (n 5 3) regions were determined by ELISA using 5 ng of rORFF.
FIGURE 4. Serologic responses of patients with cutaneous leish-
maniasis from Turkey. Sera from 10 patients with cutaneous leish-
maniasis (CL) and control sera from 3 individuals from non-endemic
regions were tested by ELISA using 5 ng of recombinant ORFF
(rORFF) with sera diluted 1:20 (left panel) or 500 ng of soluble
antigen (SA) with sera diluted 1:100 (right panel). The horizontal
bars indicate the mean titers for CL sera and the horizontal lines
indicate the cut-off values for a positive result. OD405 5 optical
density at 405 nm.
rORFF and serum diluted 1:100 or greater resulting in a
positive reading. In addition, for confirmed VL patients,
there was a positive correlation between OD405 value (pre-
sumably reflecting antibody levels) and spleen size. This lev-
el of sensitivity suggests that the antigen can be readily
adapted to other assay formats. Endpoint titers using 5 ng
of rORFF were only 2–3-fold less than using 100 ng of SA
(1:80–1:1280 versus 1:160–1:5,120). Since ORFF represents
only ;0.16% (1/600) of the total cellular protein in L. don-
ovani AG83 (Ghosh A and others, unpublished data), this
suggests that antibodies against ORFF represent a substantial
fraction of the anti-parasite immune response in VL.
The sensitivity of the rORFF-based ELISA was attested
by its ability to correctly predict the infection status of all
49 cases with clinically confirmed VL, while the DAT and
SA-based ELISA showed 1 and 11 false-negative results,
respectively. In addition, there was very good agreement be-
tween the rORFF-based ELISA and the DAT in predicting
that most (95% and 91%, respectively) patients with sus-
pected VL are indeed infected. In contrast, the SA-based
ELISA appeared less reliable (86% positive). The false-neg-
ative results in the DAT showed low OD405 values in the
rORFF ELISA (reflecting low antibody levels), but were
nonetheless positive. Thus, the rORFF-based ELISA appears
more sensitive than the DAT, which is known for a high
degree of specificity and sensitivity for VL.7,16 The slightly
elevated OD405 values for noninfected individuals from en-
demic regions compared with those from non-endemic re-
gions may reflect subclinical infection.24 Since the assay has
not yet been fully optimized with respect to antigen amount
and serum dilution, it is conceivable that an assay can be
developed that will accurately predict the parasitologic status
of all VL patients.
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The correlation between spleen size in VL patient sera
(potentially reflecting parasite burden) and OD405 value in
the rORFF ELISA provides further support for the impor-
tance of ORFF in the immune response to L. donovani in-
fection. However, all four patients who had been intermit-
tently treated for VL were strongly positive in the rORFF
ELISA, even though their spleen sizes were normal (2 cm).
This suggests that the OD405 value in the rORFF ELISA like-
ly reflects antibody levels, rather than parasite levels per se,
and may remain elevated even after spleen size has been
reduced following treatment.
The rORFF-based ELISA showed considerable specificity
for infection with L. donovani. Sera from VL patients ex-
hibited high endpoint titers with 5 ng of rORFF, while sera
from malaria, filariasis and tuberculosis patients showed
endpoint titers that were essentially indistinguishable from
healthy (presumed noninfected) non-endemic and endemic
controls. In addition, only 4 of 10 sera from patients from
Turkey with CL and confirmed to be infected with Leish-
mania (presumably L. major or L. tropica) tested positive in
the rORFF ELISA and then only marginally so. In contrast,
9 were positive with the less sensitive SA-based ELISA.
Thus, it seems likely that ORFF sequence divergence and/
or difference in expression between species allows species-
specific discrimination using the rORFF ELISA. The ORFF
is encoded in the LD1 locus chromosome 35 (;2.2 Mb) in
L. infantum and this sequence is present all Leishmania spe-
cies.25 There are only 23 amino acid differences (7%) be-
tween ORFF from L. infantum and L. major (Myler PJ, un-
published data), most of which represent conservative re-
placements. However, there is evidence for different ORFF
expression profiles between L. donovani and L. major
(Ghosh A and others, unpublished data). The ORFF is am-
plified on small (200–450 kb) linear chromosomes, circular
episomes, or a small gene conversion into the rRNA locus
in about 15% of the Leishmania isolates examined.25,26 These
gene amplifications result in increased production of ORFF
protein (Ghosh A and others, unpublished data), possibly
enhancing the use of rORFF as a serodiagnostic antigen.
While these studies demonstrate the sensitivity of rORFF
antigen for the serodiagnosis of VL in the laboratory, further
work is needed to test its utility in the field. In addition, the
nature and duration of the immune response against ORFF
needs to be more fully explored to determine whether the
rORFF ELISA can distinguish between patients with active
versus inactive VL.
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